No Picture
News

Cidara Therapeutics Selects First Clinical Development Candidate from its Cloudbreak Influenza (Antiviral) Program

SAN DIEGO–(BUSINESS WIRE)–Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company has selected the antiviral conjugate (AVC) CB-012 as its first cl… […]

No Picture
News

Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the Company has initiated ILLUMINATE-B, a global Phase 3 pediatric study of lumasiran, an investigational, subcu… […]

No Picture
News

Allele Biotechnology and SCM Lifescience Sign a Joint Research and Development Agreement to Develop iPSC-based Diabetes Treatment

SAN DIEGO–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24Cell&src=ctag" target="_blank"gt;$Celllt;/agt; lt;a href="https://twitter.com/hashtag/Allele_Biotech?src=hash" target="_blank"gt;#Allele_… […]

No Picture
News

Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases

– Developing Oral Therapies with Best-in-Class Potential — Lead Program, IMU-838, Already Advanced into Phase 2 Studies in Ulcerative Colitis and Relapsing-Remitting Multiple Sclerosis — Proceeds of approximately USD 30 million from concurrent financ… […]